Skip to Main content Skip to Navigation
Journal articles

Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.

Abstract : Development of steroid dependency in patients with nephrotic syndrome may require a long-term multi-drug therapy at risk of drug toxicity and renal failure. Rituximab treatment reduces the steroid dosage and the need for immunosuppressive therapy in pediatric patients. Here we retrospectively analyze the efficacy and safety of rituximab in adult patients with steroid-dependent minimal change disease. To do this, we analyzed the outcome of all adult patients treated with rituximab for steroid-dependent minimal change nephrotic syndrome over a mean follow-up of 29.5 months (range 5.1-82 months). Seventeen patients with steroid-dependent or frequently relapsing minimal change nephrotic syndrome, unresponsive to several immunosuppressive medications, were treated with rituximab. Eleven patients had no relapses after rituximab infusion (mean follow-up 26.7 months, range 5.1-82 months) and nine of them were able to come off all other immunosuppressive drugs and steroids during follow-up. Six patients relapsed at least once after a mean time of 11.9 months (mean follow-up 34.5 months, range 16.9-50.1 months), but their immunosuppressive drug treatment could be stopped or markedly reduced during this time. No adverse events were recorded. Thus, rituximab is efficient and safe in adult patients suffering from severe steroid-dependent minimal change disease. Prospective randomized trials are needed to confirm this study.
Document type :
Journal articles
Complete list of metadatas

Cited literature [33 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00919110
Contributor : Pierre Ronco <>
Submitted on : Monday, December 16, 2013 - 1:00:03 PM
Last modification on : Wednesday, August 19, 2020 - 11:16:37 AM
Long-term archiving on: : Saturday, April 8, 2017 - 6:45:07 AM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Citation

Helene Munyentwali, Khedidja Bouachi, Vincent Audard, Philippe Remy, Philippe Lang, et al.. Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease.. Kidney International, Nature Publishing Group, 2013, 83 (3), pp.511-6. ⟨10.1038/ki.2012.444⟩. ⟨inserm-00919110⟩

Share

Metrics

Record views

270